Best PRP Hair Treatment in Pune: Everything You Need to Know Before Getting Started
October 5, 2026
No Comments
Read More »
Written by: Dr. Kiran Chotaliya Editorial Team · Reviewed by: Dr. Kiran Chotaliya, M.D. Dermatologist & Chief Hair transplant Surgeon · Hairfree & Hairgrow Clinics, India · Updated Oct 2026
This case study documents the 6-month treatment journey of a 19-year-old male patient diagnosed with alopecia areata. Before treatment, the patient presented with extensive scalp hair loss and very limited visible hair coverage, with significant scalp exposure.
According to the provided patient profile, there was no significant medical history, and the treatment plan included Kenacort Injection for alopecia areata. Serial photographs document visible changes at approximately 1, 3, 5, and 6 months.
The case study below follows the same detailed clinical format as the reference document, including patient profile, clinical assessment, treatment plan, month-wise progress, outcome, aftercare, disclaimer, and FAQs. Pasted markdown
Patient Consent Notice
This case study has been published with the patient’s informed consent for educational and informational purposes. Appropriate measures have been taken to maintain patient privacy while presenting the scalp condition, treatment approach, and documented clinical progress.
Individual outcomes with alopecia areata treatment can vary. Hair regrowth may depend on disease activity, extent of hair loss, duration of the condition, individual response to treatment, recurrence, and other biological factors.
The result shown in this case should not be considered a guarantee of similar outcomes for every patient.
Patient Details | Information |
Age | 19 years |
Gender | Male |
Diagnosis | Alopecia Areata |
Medical History | No sgniificant medical history reported |
Initial Condition | Extensive scalp hair loss with marked scalp exposure |
Affected Area | Scalp |
Treatment Plan | Kenacort Injection |
Treatment Type | Intralesional corticosteroid treatment |
Documented Follow-Up | 1, 3, 5 and 6 months |
Latest Documented Progress | 6 months |
The patient’s alopecia areata was assessed based on the location, appearance, and extent of the localized patches.
Clinical evaluation focused on:
Serial photographs were used to document the visible treatment response over a five-month period. Pasted markdown
Before starting treatment, the patient’s clinical photographs showed marked scalp hair loss with only minimal visible hair remaining.
The baseline condition included:
This baseline served as the reference point for evaluating subsequent treatment progress.
|
Parameter
|
No. of Grafts
|
Details
|
|---|---|---|
|
|
530
|
For natural hairline
|
|
|
2480
|
Mid scalp coverage
|
|
|
3010
|
|
The patient was assessed clinically for alopecia areata according to the extent and distribution of scalp hair loss.
The clinical evaluation focused on:
Serial photographs were used during follow-up to document visible changes, consistent with the photographic monitoring approach used in the supplied reference case-study format. Pasted markdown
Following clinical evaluation, the patient was advised Kenacort Injection treatment for alopecia areata.
Kenacort contains triamcinolone, a corticosteroid that may be administered intralesionally by dermatologists in selected cases of alopecia areata. The amount, concentration, injection sites, treatment interval, and total number of sessions should be determined according to the treating dermatologist’s assessment and individual patient response. Pasted markdown
The treatment plan focused on:
Kenacort Injection was used according to the dermatologist’s treatment plan.
Treatment was directed toward affected scalp areas based on the clinical presentation.
Follow-up assessments focused on:
The photographic sequence indicates that regrowth developed gradually over several months rather than immediately.
At baseline, the patient showed extensive scalp hair loss with substantial scalp exposure.
The photographs demonstrated:
This stage served as the baseline for later comparison.
At approximately 1 month, the scalp remained highly visible and overall density was still very limited.
However, the photographs showed some short and fine hair across parts of the scalp.
Observed features included:
This represented a very early treatment stage and not the final outcome.
At the 3-month follow-up, considerably more hair was visible across the scalp compared with baseline.
The photographs showed:
At this stage, the hair was still relatively fine and coverage remained incomplete.
By approximately 5 months, the patient showed further visible improvement.
Compared with the 3-month stage:
The 5-month photographs indicate ongoing regrowth and maturation, although visible thinning was still present.
At the 6-month follow-up, there was a clear visible improvement compared with the pretreatment condition.
The photographs demonstrate:
Some scalp visibility remained over the upper and crown regions when viewed from above, indicating that this was still an ongoing treatment stage rather than a guaranteed final result.
Treatment Stage | Observed Progress |
Before Treatment | Extensive scalp hair loss with marked scalp exposure and minimal visible hair |
1 Month | Very early fine hair visible, but scalp remained largely exposed |
3 Months | Developing regrowth with improved hair distribution |
5 Months | Progressive increase in hair length and scalp coverage |
6 Months | Latest documented stage with significantly better hair coverage and reduced scalp visibility |
The patient’s serial photographs demonstrate progressive visible hair regrowth during the documented 6-month treatment journey.
At baseline, scalp exposure was extensive and only minimal visible hair remained.
During the first month, changes were limited, although fine hair could be seen in several areas. By three months, developing regrowth had become more noticeable.
Between the 3- and 5-month stages, the photographs show increasing hair length and broader scalp coverage.
By 6 months:
The 6-month photographs represent the latest documented progress, not necessarily the final outcome.
Long-term dermatologist-directed follow-up remains important in alopecia areata because the condition can have an unpredictable course.
General care may include:
The supplied reference format likewise emphasizes continued monitoring and avoiding independent changes to prescribed corticosteroid treatment. Pasted markdown
Kenacort contains triamcinolone, a corticosteroid. Intralesional corticosteroid injections may be used by dermatologists in selected alopecia areata cases, with dose, concentration, injection sites, and intervals individualized according to the patient.
Kenacort contains triamcinolone, a corticosteroid. Intralesional corticosteroid injections may be used by dermatologists for selected conditions, including localized alopecia areata and hypertrophic scars, although the technique, dose, and treatment plan differ according to the condition being treated.
Fine and short hair was visible during the 1-month follow-up, with more noticeable regrowth by approximately 3 months.
Dr. Kiran Chotaliya is a leading hair transplant surgeon in Pune, specializing in advanced techniques like FUE and FUT for natural, lasting results. His expertise and patient-centered care ensure successful hair restoration with exceptional outcomes.
© 2026 Developed & Handle By Dr. Kiran Chotaliya Clinic Team
© 2026 Developed & Handle By Dr. Kiran Chotaliya Clinic Team